Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma.

IF 3.2 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepato‐Biliary‐Pancreatic Sciences Pub Date : 2025-06-12 DOI:10.1002/jhbp.12163

Yoon Soo Chae, Youngmin Han, Go-Won Choi, Younsoo Seo, Inhyuck Lee, Won-Gun Yun, Hye-Sol Jung, Wooil Kwon, Joon Seong Park, Jin-Young Jang

{"title":"Role of Adjuvant Chemotherapy in Distal Cholangiocarcinoma.","authors":"Yoon Soo Chae, Youngmin Han, Go-Won Choi, Younsoo Seo, Inhyuck Lee, Won-Gun Yun, Hye-Sol Jung, Wooil Kwon, Joon Seong Park, Jin-Young Jang","doi":"10.1002/jhbp.12163","DOIUrl":null,"url":null,"abstract":"Background: Recent studies addressing the role of adjuvant chemotherapy (AC) in cholangiocarcinoma (CCA) have been published; however, there are challenges in generalizing the findings due to different prognostic characteristics depending on tumor location and resectability. Therefore, this study aimed to investigate the role of AC in distal cholangiocarcinoma (dCCA), a common tumor subtype of CCA.Method: Data from 497 patients with dCCA who underwent curative surgery at Seoul National University Hospital between 2000 and 2019 were reviewed using prospectively collected clinicopathologic information.Results: The median overall survival (OS) and recurrence-free survival (RFS) in the entire cohort were 62.9 and 44.0 months, respectively. AC was associated with improved five-year OS (58.5% vs. 46.4%; p < 0.001) and RFS (49.9% vs. 40.7%; p = 0.005), particularly in patients with advanced T stages (≥ T3). Multivariate analysis revealed that AC was an independent positive prognostic factor for survival. Furthermore, adjuvant radiotherapy (RT) alone provides no survival benefit, whereas AC combined with RT (AC + RT) offers greater benefits, particularly for patients with positive resection margins.Conclusion: AC improved the postoperative survival outcomes of patients with dCCA who underwent curative surgery. Furthermore, AC + RT appears to provide greater benefits, especially for patients with positive resection margins.","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepato‐Biliary‐Pancreatic Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jhbp.12163","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Recent studies addressing the role of adjuvant chemotherapy (AC) in cholangiocarcinoma (CCA) have been published; however, there are challenges in generalizing the findings due to different prognostic characteristics depending on tumor location and resectability. Therefore, this study aimed to investigate the role of AC in distal cholangiocarcinoma (dCCA), a common tumor subtype of CCA.

Method: Data from 497 patients with dCCA who underwent curative surgery at Seoul National University Hospital between 2000 and 2019 were reviewed using prospectively collected clinicopathologic information.

Results: The median overall survival (OS) and recurrence-free survival (RFS) in the entire cohort were 62.9 and 44.0 months, respectively. AC was associated with improved five-year OS (58.5% vs. 46.4%; p < 0.001) and RFS (49.9% vs. 40.7%; p = 0.005), particularly in patients with advanced T stages (≥ T3). Multivariate analysis revealed that AC was an independent positive prognostic factor for survival. Furthermore, adjuvant radiotherapy (RT) alone provides no survival benefit, whereas AC combined with RT (AC + RT) offers greater benefits, particularly for patients with positive resection margins.

Conclusion: AC improved the postoperative survival outcomes of patients with dCCA who underwent curative surgery. Furthermore, AC + RT appears to provide greater benefits, especially for patients with positive resection margins.

查看原文本刊更多论文

辅助化疗在远端胆管癌中的作用。

背景：最近有研究表明辅助化疗（AC）在胆管癌（CCA）中的作用；然而，由于肿瘤位置和可切除性不同，预后特征不同，因此在推广研究结果方面存在挑战。因此，本研究旨在探讨AC在远端胆管癌（dCCA）中的作用，远端胆管癌是CCA的常见肿瘤亚型。方法：利用前瞻性收集的临床病理信息，对2000年至2019年在首尔国立大学医院接受根治性手术的497例dCCA患者的数据进行回顾性分析。结果：整个队列的中位总生存期（OS）和无复发生存期（RFS）分别为62.9个月和44.0个月。AC与改善的5年OS相关(58.5% vs 46.4%；结论：AC改善了行根治性手术的dCCA患者的术后生存。此外，AC + RT似乎提供了更大的好处，特别是对于切除边缘阳性的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepato‐Biliary‐Pancreatic Sciences GASTROENTEROLOGY & HEPATOLOGY-SURGERY

自引率

10.00%

发文量

178

审稿时长

6-12 weeks

期刊介绍： The Journal of Hepato-Biliary-Pancreatic Sciences (JHBPS) is the leading peer-reviewed journal in the field of hepato-biliary-pancreatic sciences. JHBPS publishes articles dealing with clinical research as well as translational research on all aspects of this field. Coverage includes Original Article, Review Article, Images of Interest, Rapid Communication and an announcement section. Letters to the Editor and comments on the journal’s policies or content are also included. JHBPS welcomes submissions from surgeons, physicians, endoscopists, radiologists, oncologists, and pathologists.